Amgen Statistics
Total Valuation
Amgen has a market cap or net worth of $154.89 billion. The enterprise value is $202.70 billion.
| Market Cap | 154.89B |
| Enterprise Value | 202.70B |
Important Dates
The next estimated earnings date is Wednesday, October 29, 2025, after market close.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | Aug 22, 2025 |
Share Statistics
Amgen has 538.36 million shares outstanding. The number of shares has increased by 0.19% in one year.
| Current Share Class | 538.36M |
| Shares Outstanding | 538.36M |
| Shares Change (YoY) | +0.19% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 81.38% |
| Float | 537.00M |
Valuation Ratios
The trailing PE ratio is 23.52 and the forward PE ratio is 13.95. Amgen's PEG ratio is 2.48.
| PE Ratio | 23.52 |
| Forward PE | 13.95 |
| PS Ratio | 4.40 |
| Forward PS | 4.19 |
| PB Ratio | 20.70 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.57 |
| P/OCF Ratio | 12.86 |
| PEG Ratio | 2.48 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.55, with an EV/FCF ratio of 19.11.
| EV / Earnings | 30.62 |
| EV / Sales | 5.81 |
| EV / EBITDA | 12.55 |
| EV / EBIT | 18.88 |
| EV / FCF | 19.11 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 7.57.
| Current Ratio | 1.31 |
| Quick Ratio | 0.82 |
| Debt / Equity | 7.57 |
| Debt / EBITDA | 3.44 |
| Debt / FCF | 5.30 |
| Interest Coverage | 3.11 |
Financial Efficiency
Return on equity (ROE) is 99.14% and return on invested capital (ROIC) is 10.15%.
| Return on Equity (ROE) | 99.14% |
| Return on Assets (ROA) | 7.51% |
| Return on Invested Capital (ROIC) | 10.15% |
| Return on Capital Employed (ROCE) | 15.93% |
| Revenue Per Employee | $1.25M |
| Profits Per Employee | $236,393 |
| Employee Count | 28,000 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.47 |
Taxes
In the past 12 months, Amgen has paid $805.00 million in taxes.
| Income Tax | 805.00M |
| Effective Tax Rate | 10.84% |
Stock Price Statistics
The stock price has decreased by -12.83% in the last 52 weeks. The beta is 0.48, so Amgen's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -12.83% |
| 50-Day Moving Average | 292.94 |
| 200-Day Moving Average | 288.44 |
| Relative Strength Index (RSI) | 43.75 |
| Average Volume (20 Days) | 1,999,450 |
Short Selling Information
The latest short interest is 10.87 million, so 2.02% of the outstanding shares have been sold short.
| Short Interest | 10.87M |
| Short Previous Month | 12.52M |
| Short % of Shares Out | 2.02% |
| Short % of Float | 2.02% |
| Short Ratio (days to cover) | 5.23 |
Income Statement
In the last 12 months, Amgen had revenue of $34.92 billion and earned $6.62 billion in profits. Earnings per share was $12.23.
| Revenue | 34.92B |
| Gross Profit | 24.22B |
| Operating Income | 10.74B |
| Pretax Income | n/a |
| Net Income | 6.62B |
| EBITDA | 16.15B |
| EBIT | 10.74B |
| Earnings Per Share (EPS) | $12.23 |
Balance Sheet
The company has $8.03 billion in cash and $56.20 billion in debt, giving a net cash position of -$48.18 billion or -$89.49 per share.
| Cash & Cash Equivalents | 8.03B |
| Total Debt | 56.20B |
| Net Cash | -48.18B |
| Net Cash Per Share | -$89.49 |
| Equity (Book Value) | 7.43B |
| Book Value Per Share | 13.80 |
| Working Capital | 6.26B |
Cash Flow
In the last 12 months, operating cash flow was $12.01 billion and capital expenditures -$1.41 billion, giving a free cash flow of $10.61 billion.
| Operating Cash Flow | 12.01B |
| Capital Expenditures | -1.41B |
| Free Cash Flow | 10.61B |
| FCF Per Share | $19.70 |
Margins
Gross margin is 69.36%, with operating and profit margins of 30.75% and 18.96%.
| Gross Margin | 69.36% |
| Operating Margin | 30.75% |
| Pretax Margin | 21.26% |
| Profit Margin | 18.96% |
| EBITDA Margin | 46.25% |
| EBIT Margin | 30.75% |
| FCF Margin | 30.37% |
Dividends & Yields
This stock pays an annual dividend of $9.52, which amounts to a dividend yield of 3.31%.
| Dividend Per Share | $9.52 |
| Dividend Yield | 3.31% |
| Dividend Growth (YoY) | 5.74% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 76.78% |
| Buyback Yield | -0.19% |
| Shareholder Yield | 3.14% |
| Earnings Yield | 4.28% |
| FCF Yield | 6.86% |
Analyst Forecast
The average price target for Amgen is $320.11, which is 11.26% higher than the current price. The consensus rating is "Hold".
| Price Target | $320.11 |
| Price Target Difference | 11.26% |
| Analyst Consensus | Hold |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 3.33% |
| EPS Growth Forecast (5Y) | 26.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 22, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Nov 22, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Amgen has an Altman Z-Score of 1.68 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.68 |
| Piotroski F-Score | 7 |